Key Takeaways
- 37% revenue growth, 40% targeted next year: Q4 consolidated revenue grew 37% YoY, driven by CPVC and lead-free products, and management is targeting more than 40% growth in FY27.
- CPVC is now the growth engine: CPVC contributed 30% of total revenue, with gross margins improving from 6-7% to 18-20% as the company supplies additives to Indian pipe makers who are shifting from imported compounds to self-compounding.
- Egypt and oleo chemicals open two new frontiers: The Egypt facility starts commercial production in Q3 FY27, while oleo chemicals sales began in April 2026 with a ₹55-60 crore revenue target for FY27.
- Margins held despite raw material volatility: Gross margins stayed nearly flat QoQ even as raw material prices rose in March; the company built higher inventory to manage costs and expects to maintain 13-15% EBITDA margins in FY27.
- What to watch next quarter: The pace of oleo chemicals revenue ramp toward the ₹55-60 crore target, progress on Egypt facility commissioning, and whether CPVC margin improvement toward 20-22% materializes.
CPVC: The Margin-Rich Growth Driver
- Market structure flipped in Platinum's favor: Indian pipe manufacturers historically relied on imported CPVC compounds from Lubrizol, Sekisui and HEC, with no control over quality, price or supply. Now domestic resin capacity is coming online from players like Lubrizol/Aditya Birla, DCW, Reliance and Epigral, and Platinum supplies the additives that enable self-compounding.
- Two large customers converted: Supreme Industries and Prince Pipe and Fittings are now buying from Platinum, validating the shift from imported compounds to domestic additive supply.
- Margins transformed by in-house manufacturing: CPVC gross margins improved from 6-7% to 18-20% because Platinum manufactures most of the additives used in CPVC formulations in-house, avoiding higher market prices. Further improvement to 20-22% is possible.
- NSF approval secured: The company is now NSF approved, the American standard for CPVC products, which opens export opportunities.
- Revenue diversification in action: PVC sales were slightly lower than last year, but CPVC supported overall growth and cushioned the volatility in PVC.
Krishna Rana: "We saw all these problems, and we thought that India was coming up with the capacity of manufacturing CPVC resin... and we are the ones who are supplying the additives part of it."
Egypt Facility: Geographic Diversification with Margin Upside
- Timeline and revenue contribution: The Egypt manufacturing facility is expected to start commercial operations and begin revenue booking in Q3 FY27, contributing about 10% of topline in FY27.
- Revenue potential over time: Management expects approximately ₹300 crore revenue from Egypt over three years, with peak potential exceeding ₹600 crore.
- Margin advantage: Gross margins in Egypt will be at least at the same level as India, and management stated they will definitely be higher, driven by cost efficiencies and geographic positioning.
- Strategic rationale: The Egypt facility enables geographic diversification, cost efficiencies, and access to nearby export markets while reducing dependence on a single manufacturing geography.
Oleo Chemicals: A Second Leg of the Business
- Two years of R&D before first sale: The company researched oleo chemicals for two years before making its first sale in April 2026, with product manufactured through a contract manufacturer and sold in the market.
- FY27 revenue target: Management is targeting ₹55-60 crore revenue from oleo chemicals in FY27, expecting to reach that run rate by Q2.
- Plant investment on the horizon: Within the next one to one and a half years, after pilot sales testing, the company will invest in building its own plant for oleo-based derivatives. Design work has already started.
- Long-term ambition: Management stated that Platinum Oleo Chemicals will be as big as the current company, focusing on both domestic and international markets.
Krishna Rana: "Our Platinum Oleo Chemicals will also be as big as the current company, focusing on the domestic as well as the international markets."
Product Diversification Beyond PVC and CPVC
- New polymer additives developed: The company has developed products for other polymers beyond PVC and CPVC, including LLDPE, LDPE, HDPE and PET, broadening the addressable market.
- Life sciences division: A new life sciences division is expected to contribute to the top line in FY27.
- Portfolio logic: The diversification strategy is designed so that volatility in one polymer is offset by strength in another, reducing earnings lumpiness.
Krishna Rana: "if you see the volatility in one polymer, if the business is down, then other polymer is there to support"
Margins and Cost Management
- Gross margins held steady: Gross margins in Q4 FY26 were almost at the same level as Q3 FY26, despite raw material prices rising in March due to geopolitical factors. The company described the impact as temporary hiccups.
- Inventory strategy: In March, the company built higher inventory than normal levels, with coverage extending until May end, and is now slowly buying for June. Management stated it is able to pass on raw material costs to customers to maintain margins.
- Employee cost increase contained: Employee costs rose due to hiring for the new facility (headcount grew from approximately 120 to 150, then to 170 in April), senior-level hires to strengthen management, and normal annual increments. As a percentage of sales, the increase was only 1%.
- EBITDA margin guidance: Management expects to maintain 13-15% EBITDA margin for FY27, with no dip in margin on a long-term basis if raw material prices stabilize.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | More than 40% growth | FY27 |
| Revenue CAGR | 35% CAGR | FY26 to FY29 |
| Egypt commercial operations | Start production and revenue booking | Q3 FY27 |
| Egypt revenue contribution | ~10% of topline in FY27; ~₹300 crore over three years; peak >₹600 crore | FY27 / three years / long-term |
| Oleo chemicals revenue | ₹55-60 crore, reaching run rate by Q2 | FY27 |
| Oleo chemicals plant | Investment in own manufacturing plant | Within 1-1.5 years |
| EBITDA margin | Maintain 13-15% | FY27 |
| Egypt gross margins | At least at same level as India, definitely higher | From commencement |
| CPVC gross margins | Further improvement to 20-22% possible | Undated |
| Life sciences division | Contribute to top line | FY27 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue from operations (consolidated) | ₹132 cr, +37% YoY |
| Revenue from operations (standalone) | ₹132 cr, +60% YoY |
| EBITDA (consolidated) | ₹15.3 cr, +95% YoY |
| EBITDA margin (consolidated) | 11.6%, up 350 bps YoY |
| PAT (consolidated) | ₹14.8 cr, +164% YoY |
| PAT margin (consolidated) | 11.24%, up 543 bps YoY |
| EBITDA margin (standalone) | 12.2%, up 198 bps YoY |
| PAT (standalone) | ₹15.9 cr, +152% YoY |
| PAT margin (standalone) | 12.1%, up 439 bps YoY |
| Revenue from operations (consolidated, full year FY26) | ₹450 cr, +15% YoY |
| EBITDA (consolidated, full year FY26) | ₹59.8 cr, +4.2% YoY |
| PAT (consolidated, full year FY26) | ₹51.2 cr, +3.7% YoY |
| Revenue from operations (standalone, full year FY26) | ₹434 cr, +34% YoY |
| EBITDA (standalone, full year FY26) | ₹60 cr, +10% YoY |
| PAT (standalone, full year FY26) | ₹53.5 cr, +10% YoY |
| Net exceptional loss (fire incident at subsidiary) | ₹0.52 cr (full year FY26) |
| CPVC revenue (full year FY26) | ~₹110 cr, out of ₹450 cr total |
| CPVC monthly revenue run-rate | ₹10 cr to ₹15 cr |
| CPVC gross margin | 18% to 20%, improved from 6% to 7% two years ago; target 20% to 22% |
| Revenue mix (FY26) | 30% CPVC, 70% PVC |
| FY27 revenue growth guidance | >40%; ~10% from Egypt facility, rest from India |
| FY26 to FY29 revenue CAGR target | 35% |
| Egypt facility commercial operations start | Q3 FY27 |
| Egypt facility capacity | ~60,000 metric tonnes per annum |
| Egypt facility potential revenue | ~₹300 cr over three years; peak >₹600 cr |
| Egypt facility breakeven utilization | 30% to 35% |
| Palghar CPVC facility utilization | 70% to 80% |
| Unit 2 installed capacity (India) | ~60,000 tonnes |
| Unit 1 installed capacity (India) | ~25,000 tonnes |
| Oleo chemicals FY27 revenue target | ₹55 cr to ₹60 cr |
| Employee count | ~170 in April 2026, up from ~150 in FY26 and ~120 in FY25 |
| Employee cost as % of sales increase | 1% |
| EBITDA margin guidance | 13% to 15% |